Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Tissue-engineered bone from BMP-2-transduced stem cells derived from human fat.

Dragoo JL., Lieberman JR., Lee RS., Deugarte DA., Lee Y., Zuk PA.

Animal Study with a reported sample of 5 on Knee, published in Plast Reconstr Surg (2005) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Plast Reconstr Surg (2005)
Country
United States
Reported sample size
5
Source database
PubMed
PMID
15861072
DOI
10.1097/01.prs.0000161459.90856.ab
Citations
100

Abstract (original English)

Background Progenitor cells capable of induction into multiple mesenchymal lineages have been isolated from human liposuction aspirates. These cells, named processed lipoaspirate cells, have previously shown in vitro osteogenic capacity. The purpose of this study was to examine the in vivo bone induction capacity of bone morphogenetic protein-2 (BMP-2)-transduced processed lipoaspirate cells using adipose tissue from multiple harvest sites. Methods Processed lipoaspirate cells extracted from human abdominal and buttock liposuction aspirates (n = 5) and from infrapatellar fat pads (n = 5) were placed in osteogenic media containing Dulbecco's Modified Eagle Medium with 10% fetal bovine serum supplemented with 50 muM ascorbic acid-2-phosphate and 10 mM beta-glycerol phosphate. Half of these cells were transfected with an adenovirus carrying the cDNA for bone morphogenetic protein-2 (adBMP-2). These transfected cells were then seeded onto collagen I matrices at a concentration of 2 x 10 cells/matrix and were placed into the hind limbs of severe combined immunodeficient mice (n = 10). Nontransfected processed lipoaspirate cells were placed in the contralateral limb as a control. After 6 weeks, specimens were analyzed by radiographs, densitometry, and hematoxylin and eosin and von Kossa staining. Results The average number of cells extracted from the abdominal/buttock lipoaspirates w

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AdenoviridaeAdipose TissueAnimalsAntigens, CD34Bone Morphogenetic Protein 2Bone Morphogenetic ProteinsCalcification, PhysiologicCell DifferentiationCells, CulturedCollagen

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research